Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Quality of Life × Anastrozole × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 177 Neoplasm Metastasis 11 Neoplasms 10 Carcinoma, Intraductal, Noninfiltrating 8 Breast Neoplasms, Male 6 Breast Carcinoma In Situ 5 Advanced Breast Cancer 5 Triple Negative Breast Neoplasms 4 Endometrial Neoplasms 4 Breast Diseases 4 Ovarian Neoplasms 3 Breast Cancer Metastatic 3 Neoplasms by Site 2 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Skin Diseases 1 Sexual Dysfunction, Physiological 1 Seizures 1 Sarcoma 1 Recurrence 1 Quality of Life 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Osteoporosis 1 Multiple Endocrine Neoplasia Type 1 1 Low Grade Serous Ovarian Cancer 1 Locoregional Recurrence 1 Lethal Congenital Contracture Syndrome 2 1 Joint Diseases 1

Interventions

endostar protein 1 coenzyme Q10 1 apatinib 1 Yoga 1 Ubiquinone 1 Tamoxifen 1 Referral and Consultation 1 Palliative Care 1 Oxaliplatin 1 Melatonin 1 Exercise 1 Educational Status 1 Chemoradiotherapy 1 Capecitabine 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00784680 2009-05-01

ATAC - Quality of Life Sub-Protocol

AstraZeneca

Phase 3 Completed

Quality of Life

Data powered by HemOnc (CC BY 4.0) Colophon ⚡